Shopping Cart
There are no more items in your cart
News
Next stop: The industry's top trade shows
Agarose Bead Technologies (ABT) is excited to announce our participation in several important trade fairs this October.
Read more
Agarose Bead Technologies expands facility to meet rising global demand for novel therapies market
Agarose Bead Technologies has enhanced its Burgos facility by boosting its agarose resin production to 100,000 liters annually to position itself as a powerhouse in the novel therapies market.
Read moreSee you at Bioprocess International Conference and Exhibition 2024
ABT will be exhibiting at one of the most prestigious events in the bioprocessing industry, the Bioprocess International Conference. This prestigious event will be held...
Read more
Unveiling the role of TAOK3 and SHP-1 in T cell activation: Protein isolation and purification
Modulation of SHP-1 abundance by TAOK3 serves as a rheostat for TCR signaling and determines the activation threshold of T lymphocytes.
Read more
"The use of affinity resins is a good choice to improve and optimize the drug discovery phase in pharmaceutical companies in a time and cost-effective way"
Drug discovery is the process by which potential new therapeutic entities are identified using various scientific techniques (1).
Although it is the first step in pharmaceutical projects, drug discovery remains a long and costly process in which less than 1% of drug candidates are successful (2). For this reason, optimization in drug discovery is a major focus in the pharmaceutical industry.
In drug discovery, the identification of inhibitors of therapeutic targets is critical. One of the most important screening techniques is affinity selection-mass spectrometry (AS-MS), which facilitates the identification of small molecule ligands that act as the aforementioned inhibitors.
The optimization of this method implies the immobilization of therapeutic targets in agarose resins such as ABT Agarose Resins. For example, we can find a recent study in which the immobilization of ubiquitin-specific protease 1 (USP1) in agarose resins has boosted drug discovery in several cancer diseases (3).
Figure 1. A schematic representation of the process of immobilization and selection of the inhibitor.
USP1 is an enzyme involved in the regulation of DNA repair and is overexpressed in lung cancer, osteosarcoma and colorectal cancer, where it contributes to tumor progression and chemoresistance (4). Inhibition of USP1 has been shown to promote apoptosis in cancer cells. Thus, the immobilization of USP1 in agarose resin and its association with potent small molecule inhibitors represents a relevant improvement in pharmaceutical projects involving cancer treatments.
The methodology is simple and consists of coupling His-tagged recombinant USP1 to a Ni-NTA agarose resin, such as ABT's Nickel NTA agarose resin, in a column. A mixture of potential inhibitor molecules is then passed through the resin. The specific inhibitors bind to USP1 while the nonspecific molecules flow out. Once the resin contains only the bound USP1-inhibitor complex, it must be eluted and processed for subsequent mass spectrometric analysis and inhibitor identification (Figure 1).
All in all, as reported, the use of affinity resins is a good choice to improve and optimize the drug discovery phase in pharmaceutical companies in a time and cost-effective way.
- Zhou SF, Zhong WZ. Drug Design and Discovery: Principles and Applications. Molecules. 2017 Feb 13;22(2):279.
- Takebe T, Imai R, Ono S. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.Clin Transl Sci. 2018 Nov;11(6):597-606.
- Zhao Y, Liu M, Qin T, Peng Y, Lin G, Che C, Zhu Z. Optimizing the affinity selection mass spectrometry workflow for efficient identification and ranking of potent USP1 inhibitors. SLAS Technol. 2024 Aug;29(4):100174
- García-Santisteban I, Peters GJ, Giovannetti E, Rodríguez JA. USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. Mol Cancer. 2013 Aug 10;12:91